What to Expect in Your First Month on a GLP-1

Starting a GLP-1 medication comes with a lot of secondhand expectations — from social media, from friends, from marketing pages promising rapid transformation. The reality, according to the clinical trial data behind these medications, is more gradual and more variable than most of that content suggests. Here's what actually happens in the first month, and why.

Week 1: a deliberately low starting dose

Every GLP-1 medication starts at its lowest available dose, regardless of your eventual target dose or body size (Novo Nordisk, 2023). For semaglutide (Ozempic, Wegovy), that's 0.25 mg weekly; for tirzepatide (Mounjaro, Zepbound), it's 2.5 mg weekly. This isn't a cautious formality — the low starting dose exists specifically to let your body adjust before the medication starts working at full strength, reducing the intensity of gastrointestinal side effects (Novo Nordisk, 2023).

Many people notice reduced appetite within the first 24–48 hours of the first injection, sometimes before any real weight change (Shotsy, 2026). Side effects at this stage are typically mild or absent for most people.

Weeks 2–3: this is when side effects tend to appear

Nausea is the most commonly reported early side effect, and the trial data gives a clear picture of how common it actually is. Across the SUSTAIN diabetes trials, 15.2–24.0% of people on semaglutide 0.5 mg experienced nausea or vomiting, rising to 21.5–27.2% at the 1.0 mg dose — compared with 6.0–14.1% on comparator treatments (Lingvay et al., 2018). In the SUSTAIN 6 cardiovascular outcomes trial specifically, nausea was reported by 17.3% of people on 0.5 mg and 21.8% on 1.0 mg, versus roughly 7–8% on placebo (Marso et al., cited in NCT01720446 trial data).

These aren't rare edge-case numbers — nausea in the first few weeks is a normal, expected part of starting treatment for a meaningful minority of people, not a sign that something has gone wrong.

Week 4 and the first dose increase

Most protocols increase the dose after four weeks, following a fixed escalation schedule used across the major clinical trials — moving semaglutide from 0.25 mg to 0.5 mg, then up through 1.0 mg, 1.7 mg, and eventually 2.4 mg at four-week intervals until the target dose is reached, typically around week 16 (Novo Nordisk, 2023).

Expect a temporary return of some side effects after each increase — usually milder than the first time, and usually settling within one to two weeks (Klarity Health, 2025).

What "meaningful weight loss" actually looks like this early

If the scale hasn't moved dramatically by week 4, that's normal, not a sign of non-response. In the STEP 1 trial — the pivotal 68-week study behind Wegovy's approval — average weight loss reached 14.85% at week 68, but that number describes over a year of treatment, not the first month (Novo Nordisk, 2023). Early weight loss in the first four weeks is typically modest by comparison; the more substantial changes build over the following months as the dose titrates upward.

What genuinely warrants contacting your prescriber

Mild nausea, appetite changes, and occasional digestive discomfort are expected. Severe or persistent vomiting, inability to keep fluids down, intense abdominal pain, or side effects that don't improve within one to two weeks of a dose change are not — those are reasons to contact your prescriber, who can advise on adjusting the titration pace (Klarity Health, 2025).

What actually determines how this first month goes for you

None of the studies above measure what you eat, how you train, or how you handle the early side effects — and that's exactly where outcomes start to diverge between people on paper-identical doses.

Getting the fundamentals right from week one — adequate protein, steady hydration, and a sensible approach to the nausea window — is exactly what our While You're On It programme is built around, so the first month sets you up well rather than just being something to get through.

If nausea or reduced appetite is making it hard to eat properly in these early weeks, our Alongside Daily Support powder is formulated to help you hit protein and micronutrient targets without needing a full meal to do it.

And when you eventually reach the point of coming off treatment, our Coming Off It programme picks up the tapering and maintenance phase specifically — worth knowing about even this early, since planning for it from the start makes a real difference.

If you'd rather have someone reviewing your specific titration schedule and side effect pattern with you, our 1:1 coaching is built for exactly that kind of week-by-week support.

The bottom line

The first month on a GLP-1 is a titration month, not a transformation month. Expect a low starting dose, a real chance of nausea in weeks two and three backed by clear trial data, a dose increase around week four with a possible temporary return of side effects, and weight loss that's likely to be modest compared with what the medication eventually delivers over months of treatment. What you do around the medication in this first month — nutrition, hydration, and how you respond to side effects — matters just as much as the dose itself.

This article is for general information and isn't a substitute for medical advice. Always discuss your specific titration schedule and any side effects with your prescriber.

References

Klarity Health, Inc. (2025, September 14). What to expect when starting semaglutide: A week-by-week timeline for GLP-1 medications. https://www.helloklarity.com/post/what-to-expect-when-starting-semaglutide-a-week-by-week-timeline-for-glp-1-medications/

Lingvay, I., et al. (2018). Effect of semaglutide on body weight in subjects with and without nausea or vomiting: Post hoc analysis of the SUSTAIN trials. PubMed. https://pubmed.ncbi.nlm.nih.gov/29766634/

Novo Nordisk A/S. (2023). Research study looking at how well semaglutide works in people living with obesity and prediabetes [Clinical trial protocol]. ClinicalTrials.gov. https://cdn.clinicaltrials.gov/large-docs/71/NCT05040971/Prot_000.pdf

Trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (SUSTAIN 6). ClinicalTrials.gov, NCT01720446. https://clinicaltrials.gov/study/NCT01720446

Shotsy. (2026, March 23). What to expect in your first month on a GLP-1: A week-by-week guide. https://shotsyapp.com/what-to-expect-first-month-on-glp-1/